These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird Bio for about $29 million.

Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as ...

Shares of Viking Therapeutics VKTX rose nearly 8% on Friday after several third-party reports suggested that it was being ...

12 years after going public, beleaguered gene therapy company bluebird bio will be sold to private equity groups Carlyle and ...

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

Somerville gene therapy company bluebird bio, once among the highest-profile biotechs in the Boston area, has agreed to be ...

Bluebird Bio, Inc. (NASDAQ:BLUE), on Friday, entered into a definitive agreement to be acquired by global investment firms ...

SOMERVILLE, Mass., February 21, 2025--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird") today announced that it has entered into a definitive agreement to be acquired by funds managed by global ...

The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...